0000950170-23-033475.txt : 20230719
0000950170-23-033475.hdr.sgml : 20230719
20230719122139
ACCESSION NUMBER: 0000950170-23-033475
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230714
FILED AS OF DATE: 20230719
DATE AS OF CHANGE: 20230719
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kilcoyne Adrian
CENTRAL INDEX KEY: 0001857963
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38914
FILM NUMBER: 231096112
MAIL ADDRESS:
STREET 1: 533 AIRPORT BLVD.
STREET 2: SUITE 400
CITY: BURLINGAME
STATE: CA
ZIP: 94010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Celularity Inc
CENTRAL INDEX KEY: 0001752828
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 831702591
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 170 PARK AVE
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
BUSINESS PHONE: (908) 768-2170
MAIL ADDRESS:
STREET 1: 170 PARK AVE
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
FORMER COMPANY:
FORMER CONFORMED NAME: GX Acquisition Corp.
DATE OF NAME CHANGE: 20180912
4
1
ownership.xml
4
X0508
4
2023-07-14
0001752828
Celularity Inc
CELU
0001857963
Kilcoyne Adrian
C/O CELULARITY INC.
170 PARK AVENUE
FLORHAM PARK
NJ
07932
false
true
false
false
Chief Medical Officer
false
Class A Common Stock
2023-07-14
4
A
false
875000
0.00
A
1175000
D
These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A Common Stock. The RSUs are subject to (i) time-based vesting over a three-year period, with 25% vesting on the one-year anniversary of the grant date, 25% vesting on the two-year anniversary of the grant date, and the remainder vesting on the three-year anniversary of the grant date, and (ii) performance-based vesting based on the Issuer's stock price, and in each case subject to the Reporting Person's continuous service on each vesting date.
Reflects shares underlying RSUs subject to vesting.
/s/ Kyle Fletcher, Attorney-in-Fact
2023-07-19